Adrenomedullin stimulates nitric oxide release from SK-N-SH human neuroblastoma cells by modulating intracellular calcium mobilization

Endocrinology. 2005 May;146(5):2295-305. doi: 10.1210/en.2004-1354. Epub 2005 Jan 27.

Abstract

We used SK-N-SH human neuroblastoma cells to test the hypothesis that adrenomedullin (ADM), a multifunctional neuropeptide, stimulates nitric oxide (NO) release by modulating intracellular free calcium concentration ([Ca2+]i) in neuron-like cells. We used a nitrite assay to demonstrate that ADM (10 pM to 100 nM) stimulated NO release from the cells, with a maximal response observed with 1 nM at 30 min. This response was blocked by 1 nM ADM(22-52), an ADM receptor antagonist or 2 microM vinyl-L-NIO, a neuronal NO synthase inhibitor. In addition, 5 microM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester, an intracellular calcium chelator, eliminated the ADM-induced NO release. Similar results were observed when the cells were incubated in calcium-free medium or when L-type calcium channels were inhibited with 5 microM nifedipine or 10 microM nitrendipine. Depletion of calcium stores in the endoplasmic reticulum (ER) with 1 microM cyclopiazonic acid or 150 nM thapsigargin, or inhibition of ryanodine-sensitive receptors in the ER with 10 microM ryanodine attenuated the ADM-induced NO release. NO responses to ADM were mimicked by 1 mM dibutyryl cAMP, a cAMP analog, and were abrogated by 5 microM H-89, a protein kinase A inhibitor. Furthermore, Fluo-4 fluorescence-activated cell sorter analysis showed that ADM (1 nM) significantly increased [Ca2+]i at 30 min. This response was blocked by nifedipine (5 microM) or H-89 (5 microM) and was reduced by ryanodine (10 microM). These results suggest that ADM stimulates calcium influx through L-type calcium channels and ryanodine-sensitive calcium release from the ER, probably via cAMP-protein kinase A-dependent mechanisms. These elevations in [Ca2+)]i cause activation of neuronal NO synthase and NO release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenomedullin
  • Calcitonin Gene-Related Peptide / pharmacology
  • Calcium / metabolism*
  • Calcium Channels, L-Type / physiology
  • Chelating Agents / pharmacology
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cytoplasm / metabolism
  • Egtazic Acid / analogs & derivatives*
  • Egtazic Acid / pharmacology
  • Endoplasmic Reticulum / metabolism
  • Enzyme Inhibitors / pharmacology
  • Gene Expression
  • Humans
  • Neuroblastoma
  • Neurons / drug effects*
  • Neurons / metabolism*
  • Neurons / ultrastructure
  • Nitric Oxide / metabolism*
  • Peptide Fragments / pharmacology
  • Peptides / pharmacology*
  • RNA, Messenger / analysis
  • Receptors, Adrenomedullin
  • Receptors, Peptide / genetics
  • Ryanodine Receptor Calcium Release Channel / drug effects
  • Ryanodine Receptor Calcium Release Channel / physiology
  • Thapsigargin / pharmacology
  • Tumor Cells, Cultured

Substances

  • Calcium Channels, L-Type
  • Chelating Agents
  • Enzyme Inhibitors
  • Peptide Fragments
  • Peptides
  • RNA, Messenger
  • Receptors, Adrenomedullin
  • Receptors, Peptide
  • Ryanodine Receptor Calcium Release Channel
  • adrenomedullin (22-52)
  • calcitonin gene-related peptide (8-37)
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Adrenomedullin
  • Nitric Oxide
  • Egtazic Acid
  • Thapsigargin
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Calcitonin Gene-Related Peptide
  • Calcium